Kerwin Research Center and Memory Care focuses on the care, evaluation and treatment of memory loss and dementia due to Alzheimer’s disease and other memory disorders. The Dallas-based central nervous system provider and research site treats conditions including Alzheimer’s disease and dementia, mild cognitive impairment, vascular or stroke related dementia, Parkinson’s disease and other rare diseases such as Corticobasal degeneration, Progressive Supranuclear Palsy and Creutzfeld-Jakob disease.
Recently, a clinical-stage biotechnology company called CTD Holdings, Inc. (CTDH), a developer of cyclodextrin-based products for the treatment of disease with unmet clinical need, announced that the company has obtained a Right of Reference letter to IND 138423. The IND is for “Expanded Access to Trapposol® Cyclo™ for an Individual Patient with Late-Onset Alzheimer’s Disease,”” with investigator-sponsor Diana R. Kerwin MD, President of Kerwin Research Center.
The expanded access protocol is utilizing CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™ for the Alzheimer’s disease indication.
This study brings together Kerwin Research Center’s Dr. Diana Kerwin in partnership with CTD Holdings, the maker of Trappsol Cyclo to afford urgent access to a potential-disease modifying treatment. The collaborators will administer the product to a patient with Alzheimer’s disease who has no other disease, modifying treatment options.
CTD Holding was founded as a Florida corporation in 1990. The company anticipates launching a clinical trial program, initially in Europe, for its Trappsol®Cyclo™ in 2015 as treatment for Neiman-Pick Type C disease (NPC). They also sell cyclodextrins and related products to the life science industry, nutritional and other industries.